Panacea Biotec Ltd

₹ 376 -5.51%

15 Sep - close price

panaceabiotec.com BSE: 531349 NSE: PANACEABIO

About

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company^[1]

Key Points

Business Overview:^[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix

Website BSE NSE

Market Cap ₹ 2,302 Cr.
Current Price ₹ 376
High / Low ₹ 648 / 292
Stock P/E
Book Value ₹ 136
Dividend Yield 0.00 %
ROCE -2.44 %
ROE -2.36 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.

Cons

Stock is trading at 2.76 times its book value
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 0.47% over past five years.
Company has a low return on equity of -3.48% over last 3 years.
Earnings include an other income of Rs.26.4 Cr.
Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	129.19	143.02	150.50	136.46	115.72	147.35	163.49	132.53	166.70	141.13	165.19	166.75	199.57
	139.50	146.58	150.65	142.50	129.71	140.35	155.53	159.41	167.88	158.92	153.45	164.18	193.90
Operating Profit	-10.31	-3.56	-0.15	-6.04	-13.99	7.00	7.96	-26.88	-1.18	-17.79	11.74	2.57	5.67
OPM %	-7.98%	-2.49%	-0.10%	-4.43%	-12.09%	4.75%	4.87%	-20.28%	-0.71%	-12.61%	7.11%	1.54%	2.84%
	33.82	6.00	8.46	13.55	6.54	7.42	6.39	36.30	16.99	9.10	5.05	5.26	6.98
Interest	1.00	0.91	0.85	0.82	0.87	0.98	0.99	1.04	0.86	2.14	1.85	1.20	1.18
Depreciation	9.48	9.31	9.11	8.81	8.73	8.68	8.98	8.42	8.39	8.34	8.45	7.88	7.90
Profit before tax	13.03	-7.78	-1.65	-2.12	-17.05	4.76	4.38	-0.04	6.56	-19.17	6.49	-1.25	3.57
Tax %	15.73%	6.56%	33.33%	-6.13%	-6.86%	1.05%	-1.37%	4,875.00%	39.63%	-26.92%	40.06%	-20.00%	38.38%
	10.98	-8.29	-2.20	-1.99	-15.88	4.71	4.44	-1.99	3.96	-14.01	3.89	-1.00	2.20
EPS in Rs	1.79	-1.35	-0.37	-0.32	-2.58	0.78	0.74	-0.31	0.66	-2.27	0.65	0.08	0.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	687	653	544	593	457	544	625	661	460	559	559	640	673
	643	541	505	509	591	484	548	674	558	579	584	644	670
Operating Profit	44	112	39	84	-134	60	77	-13	-98	-20	-25	-5	2
OPM %	6%	17%	7%	14%	-29%	11%	12%	-2.0%	-21%	-3.5%	-4.4%	-0.7%	0.3%
	28	70	62	8	338	-21	9	1,687	154	62	55	36	26
Interest	105	127	101	101	105	174	185	181	4	4	4	6	6
Depreciation	67	73	68	57	54	43	46	44	39	37	35	33	33
Profit before tax	-99	-19	-67	-66	45	-178	-146	1,449	13	1	-8	-7	-10
Tax %	3%	10%	-16%	15%	17%	9%	1%	26%	363%	201%	10%	-3%
	-108	-21	-56	-76	38	-194	-148	1,078	-34	-2	-9	-7	-9
EPS in Rs	-17.38	-2.98	-8.89	-12.07	6.15	-31.69	-24.09	175.91	-5.42	-0.19	-1.37	-0.88	-1.16
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	12%
TTM:	10%

Compounded Profit Growth
10 Years:	5%
5 Years:	13%
3 Years:	21%
TTM:	43%

Stock Price CAGR
10 Years:	14%
5 Years:	5%
3 Years:	37%
1 Year:	-14%

Return on Equity
10 Years:	%
5 Years:	-10%
3 Years:	-3%
Last Year:	-2%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	6	6	6	6	6	6	6	6	6	6	6	6
Reserves	449	426	350	303	344	193	-235	871	837	836	829	829
	1,111	1,105	994	941	646	742	820	34	20	21	22	24
	364	317	440	349	379	449	587	848	407	378	433	404
Total Liabilities	1,930	1,854	1,789	1,598	1,376	1,390	1,178	1,759	1,271	1,241	1,290	1,262
	1,144	1,071	1,001	949	806	657	609	622	600	582	567	620
CWIP	155	161	30	40	23	24	34	17	42	102	128	100
Investments	15	9	7	7	5	6	0	5	13	40	3	10
	616	614	750	602	542	703	534	1,114	615	517	592	532
Total Assets	1,930	1,854	1,789	1,598	1,376	1,390	1,178	1,759	1,271	1,241	1,290	1,262

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	37	91	131	118	105	-30	107	-108	-422	-0	-27	17
	-37	16	-26	55	-6	-35	-48	1,283	430	10	65	-40
	-1	-117	-107	-164	-101	91	-47	-1,176	-18	-3	-3	-1
Net Cash Flow	-1	-10	-2	9	-2	26	12	-2	-10	7	35	-25
Free Cash Flow	30	85	107	103	100	-21	89	-119	-424	-71	-77	-37
CFO/OP	96%	64%	320%	146%	-77%	-36%	141%	-2,235%	429%	-12%	108%	-496%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	52	79	95	84	71	46	49	45	48	37	47	42
Inventory Days	404	516	770	651	173	344	311	296	292	282	391	251
Days Payable	272	318	607	540	572	463	440	327	256	244	413	247
Cash Conversion Cycle	184	278	259	195	-328	-73	-80	14	83	76	25	46
Working Capital Days	-126	27	-46	-96	-363	93	-43	-229	-5	-2	44	57
ROCE %	0%	4%	2%	3%	-16%	5%	5%	-6%	-10%	-4%	-5%	-2%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Countries Exported to (Pharmaceutical Formulations)
count ・Standalone data

xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
xx.xx	xxx.xx	xx.xx	xx.xx	xx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx
xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
xx,xxx	x,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx
x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	xxx	x,xxx	x,xxx	x,xxx
xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx	xx,xxx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
x.xx	xx.xx	x.xx	xx.xx	x.xx	x.xx	x.xx	x.xx	x.xx	xx.xx

Please log in to see hidden values.

Countries where Vaccines are Registered
count ・Standalone data

Electricity Consumption per Unit (Vaccines)
kWh per 1000 doses ・Standalone data

Patents Granted Globally
count

Pediatricians Covered
count ・Standalone data

Total Distributors (Pharma + Vaccines)
count ・Standalone data

Vaccine Production Volume
thousand doses ・Standalone data

Vaccine Segment Revenue Share
%

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	73.59%	73.59%	73.59%	73.47%	72.87%	72.49%	72.48%	72.48%	72.48%	72.48%	72.48%	72.48%
	0.26%	0.26%	0.27%	0.26%	0.37%	0.38%	1.16%	0.79%	1.06%	1.36%	1.60%	2.31%
	0.57%	0.69%	0.84%	1.07%	1.16%	1.16%	1.49%	1.52%	1.80%	1.85%	1.96%	2.25%
	25.58%	25.46%	25.30%	25.21%	25.60%	25.96%	24.86%	25.20%	24.65%	24.31%	23.96%	22.96%
No. of Shareholders	48,878	47,091	46,242	45,513	39,982	35,446	33,593	34,256	33,593	34,597	32,620	33,532

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	74.60%	74.07%	73.59%	73.59%	73.59%	73.59%	73.59%	73.59%	72.48%	72.48%	72.48%
	0.00%	0.00%	0.23%	0.00%	0.10%	0.00%	0.18%	0.27%	1.16%	1.60%	2.31%
	0.04%	0.12%	1.23%	1.61%	1.27%	0.00%	0.43%	0.84%	1.49%	1.96%	2.25%
	25.36%	25.81%	24.95%	24.79%	25.04%	26.41%	25.80%	25.30%	24.86%	23.96%	22.96%
No. of Shareholders	9,888	10,246	10,642	10,582	27,228	49,563	48,634	46,242	33,593	32,620	33,532

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Panacea Biotec Ltd

Panacea Biotec Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls